Clinical Validation of Plasma p‐217tau in Neurological Diseases

20260 citationsJournal Articlegold Open Access

Authors

Takeshi Kawarabayashi · Hirosaki University

Takumi Nakamura · Gunma University

Ryoma Takahashi · Gunma University

Tetsuya Ueda · Sumco Corporation (Japan)

Seiji Kinoshita · Sumco Corporation (Japan)

Chikage Uchida · Sumco Corporation (Japan)

Takashi Sugawara ·

Abstract

ALS and iNPH are two major pitfalls for the clinical application of plasma p-217tau as a biomarker of AD. Lower motor neuron injury in ALS and cognitive dysfunction in iNPH were both found to be associated with elevated plasma p-217tau levels.

Topics & Keywords

Amyotrophic Lateral Sclerosis Research Genetic Neurodegenerative Diseases Alzheimer's disease research and treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Annals of Clinical and Translational Neurology

DOI: 10.1002/acn3.70359

Field-Weighted Citation Impact: 0.00